

U.S. Application No. 09/936,205

**AMENDMENTS TO THE CLAIMS**

*Please amend claims as follows:*

Claims 1-8. (Canceled).

9. (Currently amended) A method for preparing an organ by perfusion prior to transplantation or storage of the organ comprising:

(i) providing an ischemic reperfusion injury prevention preparation for perfusion of an organ prior to transplantation or storage of the organ, wherein the ischemic reperfusion injury prevention preparation comprises:

(A) a soluble derivative of a soluble polypeptide, wherein the soluble derivative comprises:

(1) a fragment of complement receptor 1 (CR1), wherein the fragment has having a sequence that is set forth in SEQ ID NO: 1 and has an immunoregulatory activity, and

(2) at least two membrane binding elements, wherein (a) at least one membrane binding element is a non-peptidic membrane binding element comprising acyl groups, and (b) at least one membrane binding element is a peptidic membrane binding element comprising basic amino acids, wherein the peptidic

U.S. Application No. 09/936,205

membrane binding element is bound to the non-peptidic membrane binding element and the fragment of complement receptor 1; and

(B) a physiologically acceptable and non-reducing flush storage solution;

and

(II) ~~(C)~~ perfusing the organ with the ischemic reperfusion injury prevention preparation, wherein the organ contains the ischemic reperfusion injury prevention preparation while isolated and prior to implantation.

Claims 10-13. (Canceled).

14. (Currently amended) The method according to claim 9, wherein the physiologically acceptable and non-reducing flush storage solution comprises potassium citrate, sodium citrate, mannitol and magnesium sulphate.

15. (Canceled).

16. (Previously presented) The method according to claim 9, wherein the fragment of complement receptor 1 (CR1) has a sequence according to positions 2 to 197 of SEQ ID NO.1.

17. (Previously presented) The method according to claim 9, wherein the peptidic membrane binding element comprises a sequence selected from the

U.S. Application No. 09/936,205

group consisting of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10 and SEQ ID NO: 11.

18. (Previously presented) The method according to claim 9, wherein the non-peptidic membrane binding element comprises myristoyl.

19. (Currently amended) The method according to claim 9, wherein the organ is a kidney, a heart, a liver, or a lung.

20. (Previously presented) The method according to claim 19, wherein the organ is a human organ.

21. (Previously presented) The method according to claim 19, wherein the organ is a non-human animal organ.

22. (Previously presented) The method according to claim 9, wherein the peptidic membrane binding element comprises 8 to 20 amino acids.

23. (New) The method according to claim 9, wherein the immunoregulatory activity is a complement inhibitory activity.

24. (New) The method according to claim 14, wherein the physiologically acceptable flush storage solution is SOLTRAN.